• ALLOX closed a USD 10.5 million (EUR 9.4 million) seed financing round.
• Asabys led through its Sabadell Asabys II fund, with participation from CDTI’s SICC Innvierte and Institut Català de Finances.
• The biotechnology company uses high-throughput experimental biology and AI to discover regulatory sites on proteins for small-molecule drug development.
• Proceeds will expand its drug discovery platform, develop proprietary AI models and advance its pipeline of small-molecule therapies.
• ALLOX also appointed Morten Graugaard, chief business officer of Orbis Medicines, as independent board chair.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Asabys Partners SGEIC SA published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.